Alexander Alexandov, MD: Founder and Chief Executive Officer / Chief Medical Officer

Dr. Alexandrov has over 20 years of experience in biotech and pharmaceutical business. Prior MYR Pharma, Alexander held executive positions in the German companies Vision7and Fresenius Biotech, where he was responsible for the development of key clinical products. He started his career as a researcher at University Clinic Essen in Germany. Alexander co-founded MYR Pharma in 2011 and has been the key driver of Myrcludex B development from preclinical studies through the advanced clinical stage.  Alexander holds the degrees of Doctor of Medicine from the University of Essen, Germany and Medical Doctor from Nizhny Novgorod Medical Academy, Russia.


Jörn Möller, PhD: Chief Financial Officer

Dr. Möller is a Founder and current CFO of MYR Pharma. His background is in economics. Dr. Möller previously served as Chief Financial Officer of the German departments store chain Kaufhof, and of the Continental Group companies. Over the last two decades, he has been active as a business angel and CFO of biotechnology companies.



Alexey Eliseev, PhD, MBA:  Chief Business Officer

Alexey’s career includes 25 years of experience in academia, biotechnology industry and venture capital. Following an academic career as a Professor of Medicinal Chemistry at SUNY Buffalo, he was a co-founder of a number of successful biotechnology companies, including Alantos Pharmaceuticals (Germany/USA), AC Immune (Switzerland) and MirImmune (USA). Alexey worked with the Maxwell Biotech Venture Fund as its Managing Director and Venture Partner since 2009 and oversaw the fund’s investment in MYR Pharma. Prior to joining MYR as an executive, Alexey served as Chief Business Officer of RXi Pharmaceuticals (USA). Alexey received his PhD in Chemistry from Moscow State University and MBA from the Sloan School of Management at the Massachusetts Institute of Technology.

Clinical Advisory Board

Heiner Wedemeyer, MD (Chairman), Professor and Senior Physician, Department of Hepatology, Hannover Medical School, Hannover, Germany

Professor Wedemeyer has worked on basic and clinical aspects of hepatitis viral infections since 1996. His main interests are the immunopathogenesis of hepatitis B, hepatitis C and hepatitis D and the development of novel immunomodulatory therapies, such as therapeutic vaccines for hepatitis C. He has been involved as an Investigator in several Phase I–IV clinical trials of antiviral drugs and immunotherapies for viral hepatitis and has published more than 150 articles in peer reviewed journals. Prof. Wedemeyer joined the Governing Board of the European Association for the Study of the Liver from2008-2011 and has been appointed as EASL Secretary General from April 2009-April 2011.

Pietro Lampertico, MD, PhD, Assistant Professor of Gastroenterology, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, University of Milan, Milan, Italy

Professor Lampertico is involved in the clinical management of chronic viral hepatitis outpatients, particularly those with chronic hepatitis B. His research interests include the treatment of patients with chronic hepatitis/cirrhosis due to HBV, the long-term outcome of cirrhotic patients undergoing antiviral treatment, and the diagnosis and management of antiviral resistance to oral nucleos(t)ide analogues. Professor Lampertico is currently a reviewer for Gastroenterology,Hepatology,JournalofHepatology, and other top ranked journals, and a member of AASLD, EASL and AISF. He is currently involved in national and international HBV clinical trials.

Marion Peters, MD, Professor of Medicine and Chief of Hepatology Research at the University of California at San Francisco, USA

Dr. Marion Peters' research focuses on viral hepatitis in complicated clinical settings, patients with co-morbid conditions including alcoholism and HIV infection. In these complex situations her group focuses on the role of host responses to hepatitis virus infection, and examine the effect of alcohol or HIV on the progression of viral hepatitis and the response to anti-viral therapy. She studies the factors associated with progression of hepatitis C and HIV, including race/ethnicity, immune status and the role of reproductive aging. She has been a major scientific leader in the AIDS Clinical Trial Group (ACTG), and leads the ACTG Hepatitis Transformative Science Group and the Women’s Interagency HIV study (WIHS) Hepatitis Working group where she is studying new serum markers to evaluate liver fibrosis in women, outcomes in Hepatitis B and new HCV drugs for patients with HCV, with and without HIV.

Fabien Zoulim, MD, PhD, Medical Director of the Hepatology Department at the Hospices Civils de Lyon, Lyon, France

Fabien Zoulim obtained his M.D. in Gastroenterology and Hepatology in Lyon Medical School in 1991. He has also obtained a PhD in Molecular and Cellular Biology and was trained as a post-doctoral researcher at Fox Chase Cancer Center in Philadelphia. He is Professor of Medicine at Lyon I University since 1997. He is currently Medical Director of the Hepatology Department at the Hospices Civils de Lyon, and Scientific Director of the Department of Immunology and Virology of INSERM Unit 1052 where he is leading the team on ‘Antiviral therapy of viral hepatitis’. Dr Zoulim has served as an Associate Editor for Journal of Hepatology and is currently Associate Editor for Gut. He also served as an expert in the microbiology study section of the INSERM and ANRS, and in different national and international committees. He served as a Governing Board member of the European Association for the Study of the Liver (EASL). Dr Zoulim received the William Prusoff award of the International Society for Antiviral Research in recognition of his work in the field of HBV molecular biology and anti-HBV therapy. Furthermore, he has been the scientific coordinator of a European community-funded Network of Excellence on the management of antiviral drug resistance, and is currently involved in several European projects. Fabien Zoulim is a recognised expert in the field of viral hepatitis and antiviral therapy.